Latent Tuberculosis Infection Latent Tuberculosis Rifapentine Tuberculosis Preventive Therapy Treatment Completion Adverse Events Randomized Controlled Trial
Conditions
Interventions
Participants receive a one month daily rifapentine based regimen administered orally for latent tuberculosis infection,Participants receive a three month weekly rifapentine based regimen administered
Experimental Drug,Active Comparator Drug
One month daily rifapentine based regimen,Three month weekly rifapentine based regimen
Sponsors
Pluak Daeng Hospital Rayong
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 years or older. 2. Diagnosed with latent tuberculosis infection according to national guidelines. 3. Eligible for tuberculosis preventive therapy. 4. Able and willing to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Active tuberculosis disease. 2. Previous treatment for latent or active tuberculosis. 3. Known hypersensitivity to rifapentine or related drugs. 4. Significant liver disease. 5. Pregnancy or breastfeeding. 6. Any condition that in the investigator judgment would interfere with study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment completion rate At end of assigned treatment Proportion of participants who complete the assigned treatment regimen | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events During treatment period Number of participants experiencing adverse events during treatment,Treatment discontinuation During treatment period Proportion of participants who discontinue treatment before completion | — |
Countries
Thailand
Contacts
Public ContactChinnawat Chainual
Pluakdaeng Hospital Rayong Thailand
Outcome results
None listed